INS and type 2 diabetes mellitus: The results of a Swedish study suggested that for patients with T2DM on insulin, a higher baseline HbA1c was associated with greater FSL cost effectiveness (ICERs by baseline HbA1c: 8–9%, $29,863 USD/QALY gained; 9–12%, $19,680 USD/QALY gained) [37].